Pet Cancer Therapeutics Market Analysis

In terms of application, the pet cancer therapeutics market from mast cell cancer is set to witness over 8.5% CAGR over 2023-2032. Increased incidences of respective malignancy affecting the gastrointestinal system, bone marrow, liver, and spleen, especially in dogs, is escalating the need for cancer therapies in this tumor type. A 2022 research study found that salivary miR-21 has the potential in detecting the MCT-affected salivary gland in dogs playing the role of a biomarker for the treatment of mast cell tumors.
 

Pet cancer therapeutics market from the oral route of administration segment is projected to reach a valuation of more than USD 359 million by 2032. Notable developments in oral medicines due to their clinical benefits, including the ease & comfort of home therapy and fewer clinic visits, are bolstering segment expansion. In a recent instance, in May 2022, the FDA granted conditional approval to Laverdia-CA1 or Verdinexor tablets, the first chemotherapy pills for dogs with lymphoma. These pills can induce apoptosis and enrich the antiproliferation of cancer cells for chemotherapeutic agents.
 

By species, the pet cancer therapeutics market from the dogs segment exceeded USD 352 million in 2022 on account of the rising penetration and a spike in the occurrences of feline cancer. Moreover, risk factors related to in-breeding and non-purebred dogs have escalated the chances of tumors and lymph. In a recent 2022, the result highlighted improved lifespan of dogs as one of the major reasons for early signs of cancers due to the natural selection of protected pets with enhanced medicines and cures for illnesses. It also concluded that the increasing population of old dogs has increased the cancer ratio worldwide.
 

North America pet cancer therapeutics market is anticipated to be worth more than USD 774 million by 2032. Factors such as high veterinary health spending, an increase in the occurrences of pet cancer, and government measures to encourage pet cancer research are slated to complement regional pet cancer therapeutics sector growth. In May 2022, Petco Love, a national non-profit pet care community, along with Blue Buffalo, a pet food firm, announced a USD 1 million investment to facilitate the fight against pet cancer. The company is working with 12 university veterinary oncology partners to attain positive results in veterinary cancer treatment in the U.S.